Podcasts about Carcinoma

About this episode: For some people with a high risk of ovarian cancer, a standard approach has been full removal of the reproductive organs. But new research points to a far less invasive procedure called a salpingectomy, or removal of the fallopian tubes, as a potential “game changer” in ovarian cancer. In this episode: understanding high grade serous carcinoma—the most common type of ovarian cancer—the lack of screening tools, and why fallopian tube removal isn't yet available to more people. Guest: Dr. Rebecca Stone is an OBGYN, a professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics, and the director of The Kelly Gynecologic Oncology Service. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs, the largest center at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Game-Changer for Ovarian Cancer—Johns Hopkins Medicine Salpingectomy for ectopic pregnancy reduces ovarian cancer risk—JNCI Cancer Spectrum Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review—NIH Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

MILANO (ITALPRESS) - Al via un nuovo trattamento innovativo per la cura del carcinoma prostatico metastatico resistente alla castrazione. Si tratta della terapia con radioligandi Lutetium, per cui l'Agenzia Italiana del Farmaco ha approvato l'ammissione alla rimborsabilità. Dopo la pubblicazione in Gazzetta Ufficiale lo scorso 3 marzo, la nuova terapia sarà disponibile nelle singole regioni non appena saranno conclusi gli iter regionali. Questo traguardo rende accessibile ai pazienti affetti da carcinoma prostatico metastatico PSMA positivo la prima terapia con radioligandi, un'innovazione della medicina di precisione basata sulla teragnostica che unisce fase diagnostica e fase terapeutica in un approccio che consente di colpire in modo mirato le cellule tumorali, migliorando conseguentemente l'efficacia del trattamento e la tollerabilità per i pazienti.xm4/mgg/gtr

MILANO (ITALPRESS) - Al via un nuovo trattamento innovativo per la cura del carcinoma prostatico metastatico resistente alla castrazione. Si tratta della terapia con radioligandi Lutetium, per cui l'Agenzia Italiana del Farmaco ha approvato l'ammissione alla rimborsabilità. Dopo la pubblicazione in Gazzetta Ufficiale lo scorso 3 marzo, la nuova terapia sarà disponibile nelle singole regioni non appena saranno conclusi gli iter regionali. Questo traguardo rende accessibile ai pazienti affetti da carcinoma prostatico metastatico PSMA positivo la prima terapia con radioligandi, un'innovazione della medicina di precisione basata sulla teragnostica che unisce fase diagnostica e fase terapeutica in un approccio che consente di colpire in modo mirato le cellule tumorali, migliorando conseguentemente l'efficacia del trattamento e la tollerabilità per i pazienti.xm4/mgg/gtr

Susan Svoboda was accustomed to going in for her mammogram every November.  She enjoyed a healthy lifestyle, which included running 65 half marathons.  But in late 2021, after her mammogram, she was called to return to the doctor's office.  After scans and a biopsy, she was diagnosed with Stage 1-2 invasive ductal carcinoma.   Given her healthy routine, Susan was shocked, but she quickly had to turn her attention to her treatment.  In 2022, she underwent a successful lumpectomy.  Because of the location of the lump, and her low Oncotype DX score, the oncologist told Susan she would not have to undergo chemotherapy.  Instead, she would need to get radiation treatment, 15 rounds over three weeks; but her oncologist also suggested her regimen include estrogen inhibitor pills for the next five years.   Susan consulted reading materials and talked to numerous women who had tried the pills.  All of them had something to say that helped her to make the difficult decision to refuse the estrogen inhibitors.   Susan Svoboda found her way to survivorship.  She says that while she doesn't do half marathons, she still some light running and goes walking every day. Her journey inspired her to spend 2022 writing a book, “I Hate The Color Pink.”  She says the satisfaction that comes from writing the book is its spreading a message of information and hope.   By way of advise, Susan advises women to get their mammograms and when dealing with doctors to ask questions, lots of questions.   Addition Resources:   Susan Book, available on Amazon: “I Hate The Color Pink”

A billionaire tries to cure himself of terminal cancer, but realizes that might be harder than he thought...

ROMA (ITALPRESS) - "La certificazione Esco ha predisposto una serie di indicatori per la chirurgia del carcinoma ovarico e una conseguente classificazione dei centri ospedalieri. Il sistema di valutazione si basa su un punteggio oggettivo che tiene in considerazione le capacità chirurgiche, ma anche la sperimentazione clinica, le pubblicazioni scientifiche e altri indicatori che garantiscono sulle competenze e la preparazione di un centro, affinché il paziente sappia che può avere tutto ciò di cui ha bisogno". Lo ha detto Nicoletta Colombo, Direttrice di Ginecologia oncologica presso l'Istituto europeo di oncologia, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "Le persone non vanno identificate con la loro malattia, quindi bisogna costruire un percorso terapeutico dal punto di vista psicologico per migliorare la qualità della vita della persona. Le donne a volte decidono di curarsi presso centri non specialistici e questo è un problema culturale e di formazione della classe medica. Il centro specialistico è l'unico che può fare la diagnosi migliore". Lo ha detto Ilenia Malavasi, deputata Pd e componente Commissione Affari sociali della Camera, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr
(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "Le persone non vanno identificate con la loro malattia, quindi bisogna costruire un percorso terapeutico dal punto di vista psicologico per migliorare la qualità della vita della persona. Le donne a volte decidono di curarsi presso centri non specialistici e questo è un problema culturale e di formazione della classe medica. Il centro specialistico è l'unico che può fare la diagnosi migliore". Lo ha detto Ilenia Malavasi, deputata Pd e componente Commissione Affari sociali della Camera, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr
(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "Il problema della frammentazione della patologia ovarica è presente in ogni regione, dal punto di vista organizzativo non è semplice ricondurre tutte le attività chirurgiche necessarie in un unico centro. L'atto chirurgico può essere concentrato laddove ci sono le strutture per farlo, ma tante altre attività non richiedono di replicare in ogni singolo ospedale l'azione operatoria". Lo ha detto Sandro Pignata, Direttore di Oncologia medica presso l'Istituto nazionale tumori Pascale, intervenuto al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr
(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "La certificazione Esco ha predisposto una serie di indicatori per la chirurgia del carcinoma ovarico e una conseguente classificazione dei centri ospedalieri. Il sistema di valutazione si basa su un punteggio oggettivo che tiene in considerazione le capacità chirurgiche, ma anche la sperimentazione clinica, le pubblicazioni scientifiche e altri indicatori che garantiscono sulle competenze e la preparazione di un centro, affinché il paziente sappia che può avere tutto ciò di cui ha bisogno". Lo ha detto Nicoletta Colombo, Direttrice di Ginecologia oncologica presso l'Istituto europeo di oncologia, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "Serve una cultura della cura eccellente, su cui noi associazioni possiamo fare molto. All'interno dei centri di cura sono applicate le terapie oncologiche integrate, che non curano la malattia ma la persona. Noi sappiamo quali sono i bisogni delle pazienti e sappiamo cosa fare per loro". Lo ha detto Nicoletta Cerana, presidente di ATCO Italia, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr
(Fonte video: Utopia Studios)

ROMA (ITALPRESS) - "Serve una cultura della cura eccellente, su cui noi associazioni possiamo fare molto. All'interno dei centri di cura sono applicate le terapie oncologiche integrate, che non curano la malattia ma la persona. Noi sappiamo quali sono i bisogni delle pazienti e sappiamo cosa fare per loro". Lo ha detto Nicoletta Cerana, presidente di ATCO Italia, intervenuta al The Watcher Talk Salute, il format in onda su Urania Tv, dedicato al tema del carcinoma ovarico.fsc/gtr
(Fonte video: Utopia Studios)

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. Guests Melina Marmarelis, MD MSCE Assistant Professor Medical Director, UPenn Mesothelioma University of Pennsylvania Jia Luo, MD Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute Faculty, Brigham and Women's Hospital and Harvard Medical School

ROMA (ITALPRESS) - I dati di uno studio svolto da ricercatori dell'Istituto per l'endocrinologia e l'oncologia sperimentale del Consiglio nazionale delle ricerche e dell'Università Federico II di Napoli aggiungono un importante tassello alla comprensione delle interazioni tra il sistema immunitario e il tumore alla mammella. Si apre così la strada allo sviluppo di nuove strategie per la prognosi e la cura di questa patologia. I ricercatori, in particolare, hanno scoperto il ruolo prognostico dei linfociti T regolatori, cellule del sistema immunitario nel carcinoma mammario.col/sat/gtr

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

Discover how groundbreaking advancements in bladder cancer care are transforming lives in our latest Bladder Cancer Matters podcast episode! Host Rick Bangs kicks off BCAN's 20th anniversary "Partners in Progress" series with Karishma Parikh of Ferring Pharmaceuticals. Learn about Adstiladrin, an innovative gene therapy offering hope and bladder preservation for some patients with high-risk, BCG-unresponsive bladder cancer. With a 96% success rate in preventing progression to muscle-invasive cancer and life-changing patient stories, this episode is packed with insights into how Ferring is driving innovation, supporting patient needs, and reshaping the future of bladder cancer care. Tune in now and be inspired! ===== About Adstiladrin: INDICATION ADSTILADRIN is a treatment for adults who have all the following: High-risk non–muscle-invasive bladder cancer (NMIBC) Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy Carcinoma in situ (CIS) with or without other high-grade tumors IMPORTANT SAFETY INFORMATION Who should not receive ADSTILADRIN? Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components. What is the most important information I should know about ADSTILADRIN? Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN. What should I tell my healthcare provider? Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of ADSTILADRIN? The most common side effects of ADSTILADRIN include: Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine. These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING. What other information should I know about using ADSTILADRIN? For two days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing. For more important information, call 1-888-337-7464. Please see full Prescribing Information.

Send us a textIn our latest episode of MedStar Health DocTalk, Debra Schindler talks with MedStar Health breast surgeon, Maen Farha, MD, medical director of the Breast Center at MedStar Good Samaritan Hospital in Baltimore, about the most common breast cancer diagnosis: ductal carcinoma in situ (DCIS). Learn more about the contained, early-stage disease, the intricacies of diagnosis, and the personalized treatment options available. Dr. Farha shares valuable experience and a wealth of knowledge with hope for outstanding results, possible with proper care.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-concordant-care-for-first-line-treatment-of-a-patient-with-metastatic-urothelial-carcinoma/29195/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

BUFFALO, NY - December 4, 2024 – A new #editorial was #published in Oncotarget's Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma." Researchers Luana Guimaraes de Sousa and Renata Ferrarotto from The University of Texas MD Anderson Cancer Center made an important discovery about adenoid cystic carcinoma (ACC), a rare and aggressive cancer of the secretory glands. The study found that B7-H4, an inhibitory immune checkpoint, helps ACC tumors avoid attacks from the immune system. This discovery could lead to new treatments for ACC, which currently has very limited options for patients, especially when the cancer spreads to other organs. ACC is known for behaving in two distinct ways. The aggressive form, called ACC-I, spreads quickly to organs like the liver and lungs and leads to a short survival time of approximately three years. The less aggressive form, ACC-II, grows more slowly and often allows patients to live much longer, sometimes over 20 years. However, treatment options for both forms are limited, and once the cancer spreads, it becomes difficult to treat. The study showed that the protein B7-H4 is found at high levels in the aggressive ACC-I tumors. This protein blocks immune cells from entering the tumor, allowing the cancer to grow without being attacked by the immune system. Patients with high levels of B7-H4 in their tumors were found to have worse survival outcomes. To explore possible treatments, the researchers tested a new drug called AZD8205, designed to specifically target and block B7-H4. In preclinical tests on mice, the drug showed remarkable success. Tumors derived from patients shrank in every case, and in many cases of aggressive ACC, the tumors disappeared completely. Importantly, the drug had little effect on less aggressive ACC-II tumors, which have lower levels of B7-H4. This shows that the treatment is highly specific to tumors with high B7-H4 levels. These results have already led to clinical trials that are testing similar drugs in patients with ACC. “These trials represent attractive, rationale therapeutic opportunities for patients facing this rare, aggressive, and chemo-refractory disease, for which no systemic therapy is currently available.” In conclusion, this discovery represents a significant breakthrough in ACC research, identifying B7-H4 as a crucial factor in cancer growth and immune evasion. By leading the way for personalized treatments, it offers promising new therapeutic options and the potential for improved outcomes for ACC patients. DOI - https://doi.org/10.18632/oncotarget.28661 Correspondence to - Renata Ferrarotto - rferrarotto@mdanderson.org Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28661 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In today's episode, supported by Coherus Biosciences, we had the pleasure of speaking with Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, about the use of toripalimab-tpzi (Loqtorz) in patients with nasopharyngeal carcinoma. Dr Mekhail is the medical director of the Thoracic Cancer Program and the Associate Executive Director at the AdventHealth Cancer Institute in Orlando, Florida.  In our exclusive interview, Dr Mekhail discussed the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma, clinical successes with toripalimab in the first- and second-line nasopharyngeal carcinoma settings, and what the future looks like regarding immunotherapy in this disease.

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Yvonne's Radical Remission journey began with a stage 3C ovarian cancer diagnosis in 2019. The terminal diagnosis brought the opportunity for her to use all of the knowledge that she had acquired through the years. Not believing that she would survive due to her rapidly declining health after surgery, Yvonne followed her intuition and decided against chemo or radiation. Instead she put all of her focus on finding peace so that she could live whatever days she had left in grace. The journey to heal emotionally and spiritually, brought physical healing. Even though her oncologist gave her a prognosis of one year, Yvonne was NED in less than one year from surgery. Yvonne's journey uncovered a surprising key to healing that no one had mentioned before, authenticity. To learn more about Yonne's journey go to www.yvonnenieves.com ______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram  YouTube 

Gabriele “Gabe” Grunewald was a professional distance runner and a relentless optimist. She competed in Big Ten Championship races, became an NCAA track and field All-American athlete, and finished 4th in the 2012 U.S. Olympic Trials. Such accomplishments become even more impressive when you learn that—even as she racked up accolades and wins—Gabe also faced cancer numerous times. In 2009, Gabe was diagnosed with a rare type of cancer called adenoid cystic carcinoma (ACC). Then, in 2010, she was diagnosed with thyroid cancer. Despite these circumstances, Gabe persevered, continuing to train and run professionally. She also became a rare cancer advocate, launching the Brave Like Gabe Foundation to encourage other patients and survivors to embrace their own courage and chase their dreams. In June 2019, after a decade of living with ACC, Gabe passed away at her home in Minneapolis surrounded by loved ones—including her husband, Dr. Justin Grunewald. An ultra-marathon runner himself, Dr. Grunewald is also an internal medicine specialist and chair of the Brave Like Gabe Foundation's Rare Cancer Research Working Group. He joins the Your Stories podcast to share more about Gabe's story and legacy, along with the importance of supporting rare cancer research so that patients with these rare diseases have more hope for better outcomes.

Dr. Maritza Perez joins us on Aging Today to discuss non-melanoma skin cancer. Basal cell carcinoma and cutaneous squamous cell carcinoma are two of the most common types of cancer in the U.S. People over the age of 65 are at a greater risk for non-melanoma skin cancer, which can be removed when it's caught early, but becomes more difficult to treat at advanced stages. Being proactive about your skin health and staying vigilant about sun protection is very important.

“A lot of the efforts have been made to improve the patient experience for these treatments, as they can be given for years at a time. For example, when leuprolide debuted way back in 1985, it was a daily injection. But four years later, they developed the monthly depo formulation. Now we have formulations that are approved for administration once only every three, four, and even six months,” Andrew Ruplin, PharmD, clinical oncology pharmacist at Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the luteinizing hormone–releasing hormone (LHRH) antagonist and agonist drug classes. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by August 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to LHRH antagonists and agonists. Episode Notes  Complete this evaluation for free NCPD.  Oncology Nursing Podcast episodes: Pharmacology 101 series Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 242: Oncology Pharmacology 2023: Today's Treatments and Tomorrow's Breakthroughs Episode 154: New Drug Approvals for Metastatic Castration-Sensitive Prostate Cancer Episode 113: Manage Cancer-Related Hot Flashes With ONS Guidelines™ ONS Voice article: Oncology Drug Reference Sheet: Relugolix ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Safe Handling of Hazardous Drugs (fourth edition) Guide to Breast Care for Oncology Nurses ONS course: Safe Handling Basics ONS Guidelines™ and Symptom Interventions ONS Huddle Card: Hormone Therapy ONS Learning Libraries: Breast Cancer Cancer of the Genitourinary Tract Oral Chemotherapy Education Sheets National Comprehensive Cancer Network On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, With Illustrative Cases (by George T. Beatson) To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an Oncology Nursing Podcast™ Club in your chapter or nursing community, visit the Oncology Nursing Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Between all of these agonists and antagonists, there's a broad spectrum of applications, including hormone-positive breast cancer, androgen-deprivation therapy for prostate cancer, uterine cancer, and then other non-cancer uses like uterine fibroids, and assisted reproduction fertility treatments, and other things too.” TS 3:24 “In the education of my female patients, I basically use the analogy that it is functionally inducing menopause in that person, so there can be changes to mood and cognition, energy level fatigue, body morphology, and shifts in fat distribution metabolism, which can unfortunately increase the risk of cardiovascular disease. One that almost everyone's familiar with is hot flashes, but also changes to bone mineral density, libido and physically to atrophy and dryness of vaginal mucosa, which can make sex for our patients more difficult as well.” TS 10:33 “A concept that's familiar to all professionals in the care of prostate cancer is that because LHRH agonists cause an initial increase in testosterone, which can, in essence, feed the cancer, some patients can experience worsening symptoms of their cancer, such as difficulty voiding their bladder pain, or even vertebral collapse or spinal cord compression when bone metastases are present. This is a really serious issue that should be considered ahead of starting an agonist in these patients.” TS 12:39 “I don't think we'll see any dramatic changes in treating breast cancer, since the role of these agents is a lot more limited and simply really exist to suppress estrogen and premenopausal patients. But as a referral center that routinely sees patients with breast cancer and their 40s and 30s and even their 20s, it's crucial to consider these agents in their role for not only actively treating certain types of breast cancer, but also in preserving fertility for patients who desire to have children and they are receiving gonadotoxic chemotherapy.” TS 25:32

Creation by Ted Lapidus (1984) + Bal à Versailles by Jean Desprez (1962) + Night Flyer by Olympic Orchids (2020) + Amy Grant (1960- ) + William Friedkin's The Exorcist (1973) + Steven Spielberg's E.T. the Extra-Terrestrial (1982) + Michael Jackson's Dangerous (1991) + Dan Reed's Leaving Neverland (2019) + Ruggero Deodato's Cannibal Holocaust (1980) + Marian Dora's Cannibal (2006) + Carcinoma (2014) with Barret 4/9/22-4/25/22 S4E15, S4E17, and S4E19 7/31/24 S6E53  To hear the complete continuing story of The Perfume Nationalist please subscribe on Patreon.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RZJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 27, 2025.Navigating Recent Advances in Endometrial Carcinoma Treatment: Expert Guidance to Unleash the Power of Immunotherapy and Other Emerging Therapeutic Regimens In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

Jaycee Vallier was diagnosed with Chloroid Plexus Carcinoma, a form of Pediatric Brain Cancer on January 30th of 2020. This cancer has both limited options and a very poor outlook upon diagnosis. Unfortunately, as Jaycee's parents Curtis and Trish tell their story, these conclusions turned out to be accurate and despite going through so much for over 500 days, Jaycee lost her battle on July 3rd of 2021. Curtis and Trish will talk about their beloved daughter plus their non-profit- Battlecorn Care Packages, which they started while Jaycee was still alive and was able to help other pediatric cancer patients.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program has been supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This playlist features interviews recorded live by Oncology Data Advisor at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago. Visit oncdata.com to learn more!

Dr Rosenberg discusses current standard strategies for treating patients with nasopharyngeal cancer, the evolving role of toripalimab in this treatment paradigm, and how future advances in nasopharyngeal cancer management may impact the head and neck cancer treatment paradigm more broadly.

AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management CME Available: https://auau.auanet.org/node/41040 At the conclusion of this activity, participants will be able to: 1. Identify clinically available data that can help assess risk of UTUC disease. 2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate. 3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy. 4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes. 5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc., UroGen Pharma, Inc.

Carcinoma In Situ of the Breast  (YouTube Video # 362)  You've probably heard of “Carcinoma In Situ of the Breast.” Maybe you know it by its acronym “CIS.” But what do you really know about it? What is it? Could you explain it to someone if you had to? Well, after listening this podcast, you'll understand it, be able to explain it, and be dumbfounded by it all at the same time. 

In this captivating episode of the Bladder Cancer Matters podcast, host Rick Bangs delves into the intricacies of upper tract urothelial carcinoma with renowned experts Dr. Jeannie Hoffman-Censits and Dr. Phil Pierorazio. Together, they explore the complexities of diagnosing and treating this challenging disease, offering valuable insights into patient prognosis. The discussion highlights cutting-edge approaches, including the use of topical and systemic therapies, and sheds light on promising clinical trials. Dr. Hoffman-Censits and Dr. Pierorazio underscore the significance of personalized treatment plans and the urgent need for continued research. Don't miss this enlightening conversation that promises to deepen your understanding of upper tract urothelial carcinoma and its evolving landscape in medical care.

Drs. Alicia Morgans and Jonathan Rosenberg share their insights into some interesting abstracts from the 2024 ASCO GU symposium: one covering a model to help predict response to neoadjuvant chemotherapy in patients with muscle invasive UC, and another regarding results from the PemCab study of pembrolizumab and cabozantinib in first‑line advanced UC.

Drs. Alicia Morgans and Jonathan Rosenberg share their insights into therapeutic sequencing in patients with advanced urothelial cancer, reviewing patient selection and timing, options following progression on immunotherapy, and future therapeutic agents such as HER2‑targeted ADCs.

Drs. Rosenberg and Morgans share their insights into neoadjuvant therapy in the management of patients with muscle invasive urothelial carcinoma, including patient‑ and treatment‑related factors that may influence decision making, bladder‑preservation, and the future of neoadjuvant therapy with immunotherapy and ADCs.

In the latest episode of Investigating Breast Cancer, Dr. Adrian Lee discusses collaboration, strategies to improve treatment for ILC, and more. A BCRF investigator since 2013, he is the Pittsburgh Foundation chair and director of the Institute for Precision Medicine at the University of Pittsburgh and UPMC